Scott Ayton

List of Publications by Year
in descending order

102 papers	8,859 citations	53794 45 h-index	46799 89 g-index
106 all docs	106 docs citations	106 times ranked	10613 citing authors

#	Article	IF	Citations
1	Disruption of Hfe leads to skeletal muscle iron loading and reduction of hemoproteins involved in oxidative metabolism in a mouse model of hereditary hemochromatosis. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130082.	2.4	2
2	Selenium mediates exercise-induced adult neurogenesis and reverses learning deficits induced by hippocampal injury and aging. Cell Metabolism, 2022, 34, 408-423.e8.	16.2	58
3	Does the FDAâ€approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?. Medical Journal of Australia, 2022, , .	1.7	1
4	The Neuroinflammatory Acute Phase Response in Parkinsonianâ€Related Disorders. Movement Disorders, 2022, 37, 993-1003.	3.9	8
5	Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. Signal Transduction and Targeted Therapy, 2022, 7, 59.	17.1	88
6	Iron overload and impaired iron handling contribute to the dystrophic pathology in models of Duchenne muscular dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1541-1553.	7.3	5
7	Ventricular enlargement caused by aducanumab. Nature Reviews Neurology, 2022, 18, 383-384.	10.1	6
8	Selective ferroptosis vulnerability due to familial Alzheimerâ€™s disease presenilin mutations. Cell Death and Differentiation, 2022, 29, 2123-2136.	11.2	32
9	Apolipoprotein E potently inhibits ferroptosis by blocking ferritinophagy. Molecular Psychiatry, 2022, , .	7.9	38
10	Ferroptosis promotes T-cell activation-induced neurodegeneration in multiple sclerosis. , 2022, 19, 913-924.		51
11	Ferroptosis and its potential role in the physiopathology of Parkinsonâ€™s Disease. Progress in Neurobiology, 2021, 196, 101890.	5.7	220
12	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that intersect with pathology, APOE Îµ4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	5.7	25
13	Î²-amyloid: The known unknowns. Ageing Research Reviews, 2021, 65, 101212.	10.9	27
14	The essential elements of Alzheimerâ€™s disease. Journal of Biological Chemistry, 2021, 296, 100105.	3.4	140
15	Unblinded by the light: amyloidâ€related imaging abnormalities in Alzheimerâ€™s clinical trials. European Journal of Neurology, 2021, 28, e1.	3.3	16
16	Iron accumulation in skeletal muscles of old mice is associated with impaired regeneration after ischaemiaâ€“reperfusion damage. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 476-492.	7.3	17
17	Zinc drives vasorelaxation by acting in sensory nerves, endothelium and smooth muscle. Nature Communications, 2021, 12, 3296.	12.8	25
18	Brain volume loss due to donanemab. European Journal of Neurology, 2021, 28, e67-e68.	3.3	20

#	Article	IF	Citations
19	Iron reduces the propagation of pathological Î±â€synuclein. Journal of Neurochemistry, 2021, 159, 414-416.	3.9	1
20	Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease. Journal of Neurochemistry, 2021, 159, 804-825.	3.9	89
21	Characterization of Selenium Compounds for Anti-ferroptotic Activity in Neuronal Cells and After Cerebral Ischemiaâ€“Reperfusion Injury. Neurotherapeutics, 2021, 18, 2682-2691.	4.4	39
22	Copper and lipid metabolism: A reciprocal relationship. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129979.	2.4	26
23	Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance. Alzheimer's and Dementia, 2021, 17, 1244-1256.	0.8	71
24	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 Td (edition	9.1	1,430
25	Ferroptosis and NRF2: an emerging battlefield in the neurodegeneration of Alzheimer's disease. Essays in Biochemistry, 2021, 65, 925-940.	4.7	57
26	Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Molecular Psychiatry, 2020, 25, 2932-2941.	7.9	202
27	Brain Zinc Deficiency Exacerbates Cognitive Decline in the R6/1 Model of Huntington's Disease. Neurotherapeutics, 2020, 17, 243-251.	4.4	15
28	Cu^{II}(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease. British Journal of Pharmacology, 2020, 177, 656-667.	5.4	92
29	Fibrillar Î±-synuclein toxicity depends on functional lysosomes. Journal of Biological Chemistry, 2020, 295, 17497-17513.	3.4	30
30	Acute phase markers in CSF reveal inflammatory changes in Alzheimerâ€™s disease that are impacted by APOE Îµ4, sex and age but not pathology. Alzheimer's and Dementia, 2020, 16, e040745.	0.8	0
31	Deferiprone to delay dementia (the 3D trial). Alzheimer's and Dementia, 2020, 16, e044107.	0.8	8
32	Limited cerebral microbleeds effect on regional magnetic susceptibility measured by MRI. Alzheimer's and Dementia, 2020, 16, e044125.	0.8	0
33	Restricted Effect of Cerebral Microbleeds on Regional Magnetic Susceptibility. Journal of Alzheimer's Disease, 2020, 76, 571-577.	2.6	6
34	Cerebrospinal fluid ceruloplasmin levels predict cognitive decline and brain atrophy in people with underlying Î²-amyloid pathology. Neurobiology of Disease, 2020, 139, 104810.	4.4	24
35	Amyloidogenic processing of Alzheimerâ€™s disease Î²-amyloid precursor protein induces cellular iron retention. Molecular Psychiatry, 2020, 25, 1958-1966.	7.9	52
36	Letter to the Editor. Hyperglycolysis as a common cause for elevated lactate in subarachnoid hemorrhage. Journal of Neurosurgery, 2020, , 1-2.	1.6	1

#	Article	IF	Citations
37	Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. Breast Cancer Research, 2019, 21, 94.	5.0	87
38	Cellular Senescence and Iron Dyshomeostasis in Alzheimerâ€™s Disease. Pharmaceuticals, 2019, 12, 93.	3.8	68
39	Decreasing iron neurotoxicity in pantothenate kinase-associated neurodegeneration. Lancet Neurology, The, 2019, 18, 616-617.	10.2	3
40	Mice overexpressing hepcidin suggest ferroportin does not play a major role in Mn homeostasis. Metallomics, 2019, 11, 959-967.	2.4	7
41	Zn-DTSM, A Zinc Ionophore with Therapeutic Potential for Acrodermatitis Enteropathica?. Nutrients, 2019, 11, 206.	4.1	1
42	Axonal dispatch of iron in neuronal signaling. Nature Chemical Biology, 2019, 15, 1135-1136.	8.0	6
43	Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying Î²-amyloid pathology. Neurobiology of Disease, 2019, 124, 335-339.	4.4	39
44	Treating Alzheimer's disease by targeting iron. British Journal of Pharmacology, 2019, 176, 3622-3635.	5.4	71
45	Parkinson's disease prevalence and the association with rurality and agricultural determinants. Parkinsonism and Related Disorders, 2019, 61, 198-202.	2.2	13
46	Elevated plasma ferritin in elderly individuals with high neocortical amyloid-Î² load. Molecular Psychiatry, 2018, 23, 1807-1812.	7.9	49
47	Evidence that iron accelerates Alzheimerâ€™s pathology: a CSF biomarker study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 456-460.	1.9	66
48	P2â€473: BRAIN IRON IS A COâ€PATHOLOGY THAT IS STRONGLY ASSOCIATED WITH COGNITIVE DECLINE IN PEOPLE WITH ALZHEIMER'S PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P904.	0.8	0
49	Overcoming the Bloodâ€"Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Advanced Materials, 2018, 30, e1801362.	21.0	415
50	Current state of Alzheimerâ€™s fluid biomarkers. Acta Neuropathologica, 2018, 136, 821-853.	7.7	370
51	A Framework to Objectively Identify Reference Regions for Normalizing Quantitative Imaging. Lecture Notes in Computer Science, 2018, , 65-72.	1.3	1
52	More evidence is needed. Iron, incident cognitive decline and dementia: a systematic review. Therapeutic Advances in Chronic Disease, 2018, 9, 241-256.	2.5	14
53	Association of metals with the risk and clinical characteristics of Parkinson's disease. Parkinsonism and Related Disorders, 2018, 55, 117-121.	2.2	29
54	Marked Age-Related Changes in Brain Iron Homeostasis in Amyloid Protein Precursor Knockout Mice. Neurotherapeutics, 2018, 15, 1055-1062.	4.4	53

#	Article	IF	Citations
55	Iron and Alzheimerâ€™s Disease: An Update on Emerging Mechanisms. Journal of Alzheimer's Disease, 2018, 64, S379-S395.	2.6	205
56	Ferroptosis and cell death mechanisms in Parkinson's disease. Neurochemistry International, 2017, 104, 34-48.	3.8	260
57	Evidence of a Cardiovascular Function for Microtubule-Associated Protein Tau. Journal of Alzheimer's Disease, 2017, 56, 849-860.	2.6	23
58	Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in <i>APOE</i>-Îµ4 Carriers. JAMA Neurology, 2017, 74, 122.	9.0	61
59	Nanoscale Imaging Reveals Big Role for Iron in Alzheimerâ€™s Disease. Cell Chemical Biology, 2017, 24, 1192-1194.	5.2	13
60	Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Molecular Psychiatry, 2017, 22, 1520-1530.	7.9	449
61	A normalisation framework for quantitative brain imaging; application to quantitative susceptibility mapping. , 2017, , .		3
62	The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsonâ€™s disease. Acta Neuropathologica Communications, 2017, 5, 53.	5.2	77
63	Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Molecular Psychiatry, 2017, 22, 396-406.	7.9	66
64	[P3â€"153]: THE INFLUENCE OF AMYLOIDâ€B PRECURSOR PROTEIN PROTEOLYTIC PROCESSING ON NEURONAL IRON HOMEOSTASIS. Alzheimer's and Dementia, 2017, 13, P993.	0.8	0
65	[P1â€"444]: QUANTITATIVE SUSCEPTIBILITY MAPPING OF THE HIPPOCAMPUS PREDICTS HIPPOCAMPAL ATROPHY IN AÎ²+ ELDERLY CONTROLS AND ALZHEIMER's DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P454.	0.8	2
66	Cerebral quantitative susceptibility mapping predicts amyloid-Î²-related cognitive decline. Brain, 2017, 140, 2112-2119.	7.6	213
67	Targeting Transition Metals forÂNeuroprotection inÂAlzheimerâ€™s Disease. , 2017, , 193-215.		2
68	S-sulfocysteine/NMDA receptorâ€"dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. Journal of Clinical Investigation, 2017, 127, 4365-4378.	8.2	62
69	Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinsonâ€™s substantia nigra. Signal Transduction and Targeted Therapy, 2016, 1, 16015.	17.1	36
70	O5â€05â€01: CSF Ferritin Determines the Risk of Cognitive Decline in Preâ€Clinical <i>APOE</i>â€E4 Carriers. Alzheimer's and Dementia, 2016, 12, P387.	0.8	0
71	The Complex Role of Apolipoprotein E in Alzheimerâ€™s Disease: an Overview and Update. Journal of Molecular Neuroscience, 2016, 60, 325-335.	2.3	64
72	Typeâ€1 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease. Glia, 2016, 64, 1590-1604.	4.9	71

#	Article	IF	Citations
73	Metal-Protein Attenuating Compounds in Neurodegenerative Diseases. , 2016, , .		0
74	Serotonergic markers in Parkinson's disease and levodopaâ€induced dyskinesias. Movement Disorders, 2015, 30, 796-804.	3.9	32
75	Ferritin levels in the cerebrospinal fluid predict Alzheimerâ€™s disease outcomes and are regulated by APOE. Nature Communications, 2015, 6, 6760.	12.8	240
76	Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of Î²-Amyloid Precursor Protein. Journal of Neuroscience, 2015, 35, 3591-3597.	3.6	109
77	Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiology of Disease, 2015, 81, 168-175.	4.4	73
78	Enduring Elevations of Hippocampal Amyloid Precursor Protein and Iron Are Features of Î²-Amyloid Toxicity and Are Mediated by Tau. Neurotherapeutics, 2015, 12, 862-873.	4.4	50
79	Biometals and Their Therapeutic Implications in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 109-120.	4.4	109
80	Increased Ndfip1 in the Substantia Nigra of Parkinsonian Brains Is Associated with Elevated Iron Levels. PLoS ONE, 2014, 9, e87119.	2.5	28
81	Nigral Iron Elevation Is an Invariable Feature of Parkinsonâ€™s Disease and Is a Sufficient Cause of Neurodegeneration. BioMed Research International, 2014, 2014, 1-9.	1.9	126
82	P4-253: EVIDENCE FOR APOE PROTECTING AGAINST BRAIN IRON OVERLOAD. , 2014, 10, P878-P878.		1
83	An ironâ€“dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta. Chemical Science, 2014, 5, 2160-2169.	7.4	98
84	A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe2+ under physiologically relevant conditions. Biochimica Et Biophysica Acta - General Subjects, 2014, 1840, 3299-3310.	2.4	24
85	Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinsonâ€™s disease. Molecular Neurodegeneration, 2014, 9, 27.	10.8	60
86	Motor and cognitive deficits in aged tau knockout mice in two background strains. Molecular Neurodegeneration, 2014, 9, 29.	10.8	117
87	Ceruloplasmin and Î²-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radical Biology and Medicine, 2014, 69, 331-337.	2.9	49
88	P4-369: REVISITING THE ALZHEIMER'S AND PARKINSONISM PHENOTYPES OF TAU KO MICE: POTENTIAL GENETIC BACKGROUND EFFECT. , 2014, 10, P924-P924.		0
89	Metallostasis in Alzheimer's disease. Free Radical Biology and Medicine, 2013, 62, 76-89.	2.9	297
90	Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Annals of Neurology, 2013, 73, 554-559.	5.3	218

#	Article	IF	Citations
91	The effect of dopamine on MPTP-induced rotarod disability. Neuroscience Letters, 2013, 543, 105-109.	2.1	25
92	Amine oxidase activity of Î²-amyloid precursor protein modulates systemic and local catecholamine levels. Molecular Psychiatry, 2013, 18, 245-254.	7.9	14
93	A delicate balance: Iron metabolism and diseases of the brain. Frontiers in Aging Neuroscience, 2013, 5, 34.	3.4	314
94	Zinc in Alzheimerâ€™s and Parkinsonâ€™s Diseases. , 2013, , 2433-2441.		0
95	The AÂ-Induced NFAT Apoptotic Pathway Is Also Activated by GSK-3 Inhibition: Implications for Alzheimer Therapeutics. Journal of Neuroscience, 2012, 32, 9454-9456.	3.6	6
96	PBT2 Reduces Toxicity in a C. elegans Model of polyQ Aggregation and Extends Lifespan, Reduces Striatal Atrophy and Improves Motor Performance in the R6/2 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 211-219.	1.9	57
97	The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinsonâ€™s disease. Journal of Experimental Medicine, 2012, 209, 837-854.	8.5	151
98	Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nature Medicine, 2012, 18, 291-295.	30.7	491
99	GSK-3 in Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	2.0	119
100	Î±-Synuclein Transgenic Mice Reveal Compensatory Increases in Parkinson's Disease-Associated Proteins DJ-1 and Parkin and Have Enhanced Î±-Synuclein and PINK1 Levels After Rotenone Treatment. Journal of Molecular Neuroscience, 2010, 42, 243-254.	2.3	37
101	Tau protein: Relevance to Parkinson's disease. International Journal of Biochemistry and Cell Biology, 2010, 42, 1775-1778.	2.8	180
102	Serotonergic lesions of the dorsal hippocampus differentially modulate locomotor hyperactivity induced by drugs of abuse in rats: implications for schizophrenia. Psychopharmacology, 2009, 206, 665-676.	3.1	10